DOP056 Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn’s disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study | Zendy

AI Assistant Blog Pricing

DOP056 Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn’s disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.